PhD-student Robert Macsics examining an agar plate on which colonies of the Staphylococcus aureus bacteria have grown. The color change of the plate from red to yellow in the area of the bacterial colonies indicates that they are bacteria of the species S. aureus.
PhD-student Robert Macsics examining an agar plate on which colonies of the Staphylococcus aureus bacteria have grown. The color change of the plate from red to yellow in the area of the bacterial colonies indicates that they are bacteria of the species S. aureus.
Image: Andreas Heddergott / TUM
  • Research news
  • Reading time: 2 MIN

Modified cancer drug effective against multi-resistant bacteriaFrom cancer medication to antibiotic

Antibiotic-resistant bacteria are increasingly the source of deadly infections. A team of scientists from the Technical University of Munich (TUM) and the Helmholtz Center for Infection Research (HZI) in Braunschweig have now modified an approved cancer drug to develop an active agent against multidrug-resistant pathogens.

The methicillin-resistant Staphylococcus aureus (MRSA) is the source of severe and persistent infections. Some strains are even resistant to multiple antibiotics. There is consequently an urgent need for new drugs effective against MRSA infections.

"The industrial development of new antibiotics is stalling and not keeping pace with the spread of antibiotic resistance. We urgently need innovative approaches to meet the need for new infection therapies that do not lead directly to renewed resistance," says Prof. Eva Medina, director of the HZI Infection Immunology Research Group.

New antibiotic development strategies

One promising strategy is to test the potential effect of approved drugs on bacteria. “Our focus was on a class of human proteins, called kinases, which have many inhibitors to begin with," explains study leader Stephan Sieber, professor of organic chemistry at TUM.

In this vein, the researchers chemically modified the active ingredient sorafenib, a cancer drug that is effective against MRSA, to achieve a stronger antibiotic effect. This led to the development of PK150, a molecule ten times more effective against MRSA than the original substance.

Multiple attacks prevent the development of resistance

The potent new agent targets various unconventional structures within the bacteria. Two targets were investigated in greater detail: For one, PK150 inhibits an essential protein involved in bacterial energy metabolism. For another, it acts on the cell wall.

In contrast to previously known antibiotics such as penicillin and methicillin, which interfere with cell wall formation, PK150 acts indirectly. It knocks the protein production in bacteria off kilter. As a result, the bacteria release more proteins that control the cell wall thickness to the outside, causing the cells to burst.

In mice, PK150 has proven to be effective against MRSA in a variety of tissues. While staphylococci rapidly develop resistance to other antibiotics, the researchers did not observe the development of any resistance to PK150.

Effectiveness against biofilms and persisters

Eva Medina and Dr. Katharina Rox, a pharmacologist from the Department of Chemical Biology at HZI, showed that PK150 has favorable pharmacological properties. It can be administered as a tablet, for example, and remains stable in the body for several hours. "As a result of the chemical changes to the molecule, PK150 no longer binds to human kinases, but acts very specifically against bacterial targets," says Sieber.

And PK 150 has another benefit: "MRSA infections are very often chronic, as the bacteria can become dormant. PK150 even kills these, as well as germs protected in biofilms," says Prof. Dietmar Pieper, head of the HZI research group "Microbial Interactions and Processes".

In the context of the aBACTER project, Prof. Sieber's team is now further optimizing PK150 to enter the clinical development phase.

Publications:

Repurposing human kinase inhibitors to create an antibiotic active against drug-resistant Staphylococcus aureus, persisters and biofilms
Philipp Le, Elena Kunold, Robert Macsics, Katharina Rox, Megan C. Jennings, Ilke M. Ugur, Maria Reinecke, Diego Chaves-Moreno, Mathias W. Hackl, Christian Fetzer, Franziska A. M. Mandl, Johannes Lehmann, Vadim S. Korotkov, Stephan M. Hacker, Bernhard Kuster, Iris Antes, Dietmar Pieper, Manfred Rohde, William M. Wuest, Eva Medina, Stephan A. Sieber
Nature Chemistry, 16.12.2019 – DOI: 10.1038/s41557-019-0378-7

More information:

The work was funded by the European Community (via the European Research Council (ERC) and the CHEMMINE research program), the German Research Foundation (DFG) within the Cluster of Excellence Center for Integrated Protein Science Munich (CIPSM) and the SFB 1035 Collaborative Research Center, the Chemical Industry Fund, the Boehringer Ingelheim Fund, the German Center for Infection Research (DZIF), the National Science Foundation (NSF) and the National Institute of General Medical Sciences (the latter two, USA). The aBACTER project is funded by the German Federal Ministry of Education and Research (BMBF) as part of the VIP + program.

In addition to the Chair of Organic Chemistry, the Chair of Proteomics and Bioanalytics, and Radiochemistry Munich of the TUM, various working groups of the Helmholtz Center for Infection Research, the German Center for Infection Research, the German Cancer Research Center (DKFZ), Temple University (Philadelphia, USA), and Emory University (Atlanta, USA) participated in the research. Stephan Sieber is also scientifically associated with the Helmholtz Institute for Pharmaceutical Research Saarland (HIPS), an HZI site in cooperation with the University of Saarland, and the Institute for Advanced Study of the TUM.

High resolution image

Corporate Communications Center

Technical University of Munich Dr. Andreas Battenberg
battenberg(at)zv.tum.de

Contacts to this article:

Prof. Dr. Stephan A. Sieber
Technical University of Munich
Professorship of Organic Chemistry II
Lichtenbergstr. 4, 85748 Garching, Germany
Tel.: +49 89 289 13302
stephan.sieber@tum.de

Article at tum.de

Prof. Dr. Stephan A. Sieber

Stephan A. Sieber receives Future Insight Prize

Stephan A. Sieber, Professor for Organic Chemistry at the Technical University of Munich (TUM) has been awarded the 2020 Future Insight Prize for his research on the development of new strategies against multidrug-resistant...

Three cryo-electron microscopic views of the protein complex ClpX-ClpP.

Weak spot in pathogenic bacteria

Antibiotics are still the most important weapon for combatting bacterial infections. But medical science is running out of “ammunition” because of more and more frequently occurring resistances. A research team has now...

Prof. Stephan A. Sieber und Dr. Sabine Schneider im Labor des Lehrstuhls für Organische Chemie II der TU München. (Bild: A. Battenberg / TUM)

New targets in the battle against antibiotic resistance

More and more bacteria are resistant to available antibiotics. A team of chemists from the Technical University of Munich (TUM) now presents a new approach: they have identified important enzymes in the metabolism of...

Richtfest zum Neubau des Protein-Forschungszentrums auf dem Campus in Garching: Prof. Stephan Sieber, stv. Leiter des Zentrums, Thomas Rachel, MdB, Parlamentarischer Staatssekretär im Bundesministerium für Bildung und Forschung, Alfons Kraft zweiter Bürgermeister der Stadt Garching, TU-Präsident Wolfgang A. Herrmann und Ilse Aigner, bayerische Staatsministerin für Wohnen, Bau und Verkehr (v.l.n.r.). (Foto: A. Heddergott)

Top-notch protein research

With the construction of the new protein research center in Garching, the Technical University of Munich (TUM) is strengthening its biomedical research.  At the topping-out ceremony on August 30, 2018, TUM President...

Dr. Johannes Lehmann (links) und Prof. Sephan A. Sieber begutachten Testergebnisse zur antibakteriellen Wirkung verschiedener Substanzen. (Foto: Christian Fetzer / TUM)

Double strike against tuberculosis

In search of new strategies against life-threatening tuberculosis infections, a team from the Technical University of Munich (TUM), as well as Harvard University and Texas A&M University in the USA have found a new ally....

Das Ziel des Angriffs: die Protease ClpP - Bild: M. Gersch / TUM

Two new weapons in the battle against bacteria

Proteases are vital proteins that serve for order within cells. They break apart other proteins, ensuring that these are properly synthesized and decomposed. Proteases are also responsible for the pathogenic effects of many...